KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Inventory (2018 - 2025)

Historic Change in Inventory for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q3 2025 value amounting to -$5.0 million.

  • Alnylam Pharmaceuticals' Change in Inventory rose 1601.69% to -$5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.2 million, marking a year-over-year increase of 625.53%. This contributed to the annual value of -$13.6 million for FY2024, which is 2600.86% up from last year.
  • Alnylam Pharmaceuticals' Change in Inventory amounted to -$5.0 million in Q3 2025, which was up 1601.69% from -$11.1 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Change in Inventory registered a high of $19.0 million during Q4 2022, and its lowest value of -$12.0 million during Q4 2023.
  • For the 5-year period, Alnylam Pharmaceuticals' Change in Inventory averaged around $329421.1, with its median value being -$1.9 million (2022).
  • Its Change in Inventory has fluctuated over the past 5 years, first soared by 38972.7% in 2021, then tumbled by 2815000.0% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Change in Inventory stood at $10.8 million in 2021, then skyrocketed by 76.38% to $19.0 million in 2022, then tumbled by 163.18% to -$12.0 million in 2023, then skyrocketed by 92.92% to -$849000.0 in 2024, then tumbled by 486.1% to -$5.0 million in 2025.
  • Its Change in Inventory was -$5.0 million in Q3 2025, compared to -$11.1 million in Q2 2025 and -$6.2 million in Q1 2025.